The new Greenback: Why investors are getting high on medicinal cannabis firmsPosted by On


Avihu Tamir is CEO of Kanabo

For years, advocates of medicinal cannabis products have predicted that the industry is set to revolutionise healthcare – and make investors a tidy profit. That time may finally be coming.

Take our firm, Kanabo Group, which became the first medicinal cannabis company to get approval from the Financial Conduct Authority last month to list on the London Stock Exchange, on 16 February, subject to shareholder approval.

Read more: David Beckham-backed cannabis firm on course to become LSE’s first CBD listing

It has conditionally raised £6,000,000 in an oversubscribed placing and getting FCA approval was the culmination of several years of hard work.

The go-ahead is not just a huge milestone for Kanabo, but also for the UK market as well. For several years, America and Canada have been leading the charge when it comes to medicinal cannabis, creating thousands of jobs and billions in taxable revenue.

The FCA published guidelines in September last year allowing cannabis companies to list on the LSE, as long as they are medicinal or pure CBD companies, with no recreational business allowed. So now it is time for the UK and Europe to start catching up and this month has seen the start of that, with a slew of cannabis companies beginning to seek admission to the LSE.

Kanabo has developed the VapePod, the only medical…

Original Author Link click here to read complete story..

Avihu Tamir is CEO of Kanabo

For years, advocates of medicinal cannabis products have predicted that the industry is set to revolutionise healthcare – and make investors a tidy profit. That time may finally be coming.

Take our firm, Kanabo Group, which became the first medicinal cannabis company to get approval from the Financial Conduct Authority last month to list on the London Stock Exchange, on 16 February, subject to shareholder approval.

Read more: David Beckham-backed cannabis firm on course to become LSE’s first CBD listing

It has conditionally raised £6,000,000 in an oversubscribed placing and getting FCA approval was the culmination of several years of hard work.

The go-ahead is not just a huge milestone for Kanabo, but also for the UK market as well. For several years, America and Canada have been leading the charge when it comes to medicinal cannabis, creating thousands of jobs and billions in taxable revenue.

The FCA published guidelines in September last year allowing cannabis companies to list on the LSE, as long as they are medicinal or pure CBD companies, with no recreational business allowed. So now it is time for the UK and Europe to start catching up and this month has seen the start of that, with a slew of cannabis companies beginning to seek admission to the LSE.

Kanabo has developed the VapePod, the only medical…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.